Barbara A Burckhartt, MD | |
2451 Fillingim St, Bldg. C, Mobile, AL 36617-2238 | |
(251) 445-8242 | |
(251) 445-8250 |
Full Name | Barbara A Burckhartt |
---|---|
Gender | Female |
Speciality | Internal Medicine - Cardiovascular Disease |
Location | 2451 Fillingim St, Mobile, Alabama |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861442014 | NPI | - | NPPES |
009904845 | Medicaid | AL | |
009906905 | Medicaid | AL | |
1538558 | Medicaid | LA | |
00119629 | Medicaid | MS | |
51512534 | Other | AL | BCBS |
51518570 | Other | AL | BCBS |
25-10764 | Other | AL | UNITED HEALTHCARE |
265551900 | Medicaid | FL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 16748 (Alabama) | Primary |
Entity Name | University Of South Alabama Health Services Foundation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962455881 PECOS PAC ID: 8426957952 Enrollment ID: O20040105000373 |
News Archive
The success of HIV treatment programs depends upon the identification, enrollment, and retention of HIV-infected individuals, but public health officials have learned that there are numerous barriers to such success at every point in this care continuum.
Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.
A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration
Discovery Laboratories, Inc. is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
› Verified 5 days ago
Entity Name | University Of South Alabama |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992746838 PECOS PAC ID: 3072425149 Enrollment ID: O20040115000773 |
News Archive
The success of HIV treatment programs depends upon the identification, enrollment, and retention of HIV-infected individuals, but public health officials have learned that there are numerous barriers to such success at every point in this care continuum.
Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.
A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration
Discovery Laboratories, Inc. is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
› Verified 5 days ago
Entity Name | Usa Health Physician Billing Services Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1720645468 PECOS PAC ID: 9931436912 Enrollment ID: O20190814000827 |
News Archive
The success of HIV treatment programs depends upon the identification, enrollment, and retention of HIV-infected individuals, but public health officials have learned that there are numerous barriers to such success at every point in this care continuum.
Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.
A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration
Discovery Laboratories, Inc. is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Barbara A Burckhartt, MD Po Box 40480, Mobile, AL 36640-0480 Ph: (251) 445-8242 | Barbara A Burckhartt, MD 2451 Fillingim St, Bldg. C, Mobile, AL 36617-2238 Ph: (251) 445-8242 |
News Archive
The success of HIV treatment programs depends upon the identification, enrollment, and retention of HIV-infected individuals, but public health officials have learned that there are numerous barriers to such success at every point in this care continuum.
Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.
A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration
Discovery Laboratories, Inc. is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
› Verified 5 days ago
Damian Joseph Collins, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 Spring Hill Ave, Suite 100, Mobile, AL 36604 Phone: 251-435-1200 Fax: 251-435-6357 | |
Lenore Landers Pierce, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6801 Airport Blvd, Mobile, AL 36608 Phone: 251-639-5775 Fax: 251-631-3581 | |
Peter Chestnutt Coats, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 6701 Airport Blvd, Suite A-101, Mobile, AL 36608 Phone: 251-633-8880 Fax: 251-634-4502 | |
Mr. Stephen Reeves Dill, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6801 Airport Blvd # 11n, Mobile, AL 36608 Phone: 251-445-2412 Fax: 850-981-1878 | |
Dr. Dale Scott Kirby Jr., MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd, Suite D-330, Mobile, AL 36608 Phone: 251-607-9797 Fax: 251-607-9761 | |
Sandeep Vidyadhar Bhadkamkar, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6801 Airport Blvd, Mobile, AL 36608 Phone: 251-266-3580 Fax: 251-266-3581 | |
Reynaldo Rodriguez, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3601 Springhill Business Park, Mobile, AL 36608 Phone: 251-873-6192 Fax: 251-873-6193 |